BGB A317

Drug Profile

BGB A317

Alternative Names: BGB-A317

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fc receptor modulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Hodgkin's disease; Oesophageal cancer; Urogenital cancer
  • Phase I B cell lymphoma; Solid tumours

Most Recent Events

  • 09 Aug 2017 Phase-II clinical trials in Gastric cancer and Oesophageal cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (Parenteral)
  • 05 Jul 2017 Celgene Corporation and BeiGene collaborate on BGB A317 for Solid tumours
  • 05 Jul 2017 Phase-II clinical trials in Urogenital cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top